Silence Therapeutics September 2022 Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions ...

Silence Therapeutics July 13, 2022 Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions. ...

Silence Therapeutics plc (NASDAQ:SLN) Q4 2021 Earnings Conference Call March 17, 2022 8:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations and Corporate Communications Craig Tooman - President and Chief Executive Officer Rhonda Hellums - Chief Financial Officer Giles Campion - Head of R&D Conference Call Participants Tom Shrader - BTIG Patrick Trucchio - H.C. Wainright Myles Minter - William Blair Operator Good day, ladies and gentlemen, and welcome to the Silence Therapeutics Full Year ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

| --- | --- | |----------------------------------------------------------|-------| | | | | | | | | | | March 2022 Corporate Presentation Silence Therapeutics | | Forward-Looking Statements 2 The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by l ...

Financial Data and Key Metrics Changes - For the six-month period ending June 30, 2021, the company recorded revenues of £5.8 million, a significant increase from £1.1 million in the same period of 2020, primarily due to partnership programs with Mallinckrodt and AstraZeneca [27] - The company's net loss for the six months ended June 30, 2021, was £20 million, compared to £11 million for the same period in 2020, driven by increased investments in R&D and general administrative costs [32] - Cash, cash equivalents, and deposits were £81.2 million at the end of June 2021, including net proceeds of approximately £30.7 million from a financing round and £30.8 million received from AstraZeneca [33] Business Line Data and Key Metrics Changes - The proprietary pipeline achieved a historic milestone with the first clinical data from the GOLD platform, specifically the SLN124 healthy volunteers study, demonstrating the technology's potential [7] - The company advanced its partnered pipeline, initiating work on a second undisclosed target with AstraZeneca and starting the third target under the Mallinckrodt collaboration [8] Market Data and Key Metrics Changes - The SLN360 program for cardiovascular disease due to high levels of lipoprotein(a) (Lp(a)) has fully enrolled four cohorts in a single ascending dose study, with topline data expected in Q3 2022 [12] - The SLN124 program for thalassemia and myelodysplastic syndrome (MDS) is expected to present additional results at the ASH conference in December, pending abstract acceptance [13] Company Strategy and Development Direction - The company aims to maximize the opportunity of its proprietary mRNAi GOLD platform, targeting disease-associated views in the liver through a hybrid model of proprietary and partnered pipelines [6] - The company is committed to delivering two to three INDs per year starting in 2023, focusing on liver-oriented programs [58] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong clinical data and a robust cash position that should fund operations through at least the end of 2022 or early 2023 [34][35] - The company is focused on advancing its clinical pipeline and believes the GOLD platform has significant potential for developing new precision medicines [10] Other Important Information - The company plans to host an R&D Day in New York on October 21, where it will discuss the SLN124 and SLN360 programs in more detail [16] - The increase in general administrative costs was primarily due to expenses associated with the NASDAQ listing and the requirements of being a public company [31] Q&A Session Summary Question: Regarding the SLN124 program and hemoglobin changes - Management indicated that a 30% reduction in transfusion frequency would likely be the registration endpoint, with a 1 to 1.5 gm increase in hemoglobin being clinically relevant [41] Question: On the SLN360 clinical development plan - The company is on track to initiate a Phase 2 study for SLN360 in the second half of next year, subject to regulatory discussions [46] Question: Advantages of SLN124 compared to other modalities - Management highlighted the strong target knockdown, long duration of action, and good safety profile of siRNA as advantages over other approaches [51] Question: Future INDs and target selection - The company plans to focus on liver-oriented programs for the upcoming INDs, leveraging its internal pipeline and partnerships [58] Question: Updates on AstraZeneca and Takeda collaborations - The company is bound by partnership agreements regarding the disclosure of targets and is progressing well in its collaborations [69][70]

| --- | --- | |-------|-------| | | | | | | Forward-Looking Statements 2 The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Silence Therapeutics FY20 Results March 30, 2021 Forward-Looking Statements 2 The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any su ...

Silence Therapeutics plc (NASDAQ:SLN) Q4 2020 Results Earnings Conference Call March 30, 2021 8:00 AM ET Company Participants Gem Hopkins - Head, Investor Relations and Corporate Communications Mark Rothera - President and CEO Craig Tooman - Chief Financial Officer Dr. Giles Campion - Head, R&D and CMO Conference Call Participants Julian Harrison - BTIG Patrick Trucchio - H.C. Wainwright Miles Dixon - Peel Hunt Myles Minter - William Blair Operator Good day, ladies and gentlemen. And welcome to the Silence ...